In one of the earliest studies, the combination of encorafenib, cetuximab, and nivolumab was related to an ORR of 45% in patients with chemotherapy-refractory unresectable or metastatic MSS, BRAF-V600E mutated CRC, while the combination of atezolizumab and cobimetinib was related to an ORR of 3% in patients with previously treated metastatic MSS CRC in the IMblaze 370 study.51,67 Five additional studies evaluated the efficacy of radiotherapy plus ICI combinations. Here, BRAF is linked to Marinesco-Sjogren syndrome.